Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Hodgkin Disease 65 Lymphoma 39 Urinary Bladder Neoplasms 16 Carcinoma, Non-Small-Cell Lung 10 Melanoma 9 Lung Neoplasms 9 Urethral Neoplasms 4 Recurrence 4 Prostatic Neoplasms 4 Lymphoma, Large-Cell, Anaplastic 4 Testicular Neoplasms 3 Neoplasms 3 Leukemia 3 Glioma 3 Central Nervous System Neoplasms 3 Astrocytoma 3 Testicular Germ Cell Tumor 2 Teratoma 2 Skin Neoplasms 2 Oligodendroglioma 2 Neurofibromatosis 1 2 Kidney Neoplasms 2 HIV Infections 2 Carcinoma, Renal Cell 2 Breast Neoplasms 2 Brain Neoplasms 2 Uterine Cervical Neoplasms 1 Urothelial Carcinoma of the Bladder 1 Ureteral Neoplasms 1 Survival Without Progression 1

Interventions

Vinblastine 1 Methotrexate 1 Cyclophosphamide 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Survival Without Progression × Vinblastine × Clear all

NCT01285817 2023-03-13

SFCE METRO 01

Assistance Publique Hopitaux De Marseille

Phase 2 Completed

Survival Without Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡